Ultrashort Versus 1-Year Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Meta-analysis of Randomized Controlled Trials.

ABSTRACT:

Background

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard antithrombotic therapy after percutaneous coronary intervention (PCI); however, the optimal duration of this treatment remains a topic of ongoing debate. This study aimed to assess the clinical utility of an ultrashort dual antiplatelet therapy (US-DAPT) regimen (≤1 month) compared with standard DAPT (≥6 months) after PCI. In addition, the outcomes of choosing single antiplatelet therapy after US-DAPT, either clopidogrel or ticagrelor, were also analyzed.

Methods

We queried MEDLINE, Cochrane Central Registry of Controlled Trials, Embase, and ClinicalTrials.gov databases from their commencement to May 2024 for all randomized controlled trials (RCTs) that directly compared

SUBMITTER: Dodoo SN 

PROVIDER: S-EPMC11916820 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature